BioSpace News Archive

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans aQ4 2022 IND filingfor OK-101 to treat dry eye disease, with AmbioPharm playing a key role in peptide manufacturing and development.

Opthea Limited reported financial results for the fiscal year ended June 30, 2022 and provided an overview of recent progress.

Sangamo Therapeutics, Inc., a genomic medicine company, announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

I-Mab will host conference calls and webcasts on August 30, 2022. A Mandarin session will be held at 7:00 a.m. ET and an English session will be held at 8:15 a.m. ET.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 1:30 p.m. EST.

Veeva Systems (NYSE: VEEV) today announced that Veranex is using Veeva Vault CDMS to speed study builds and simplify clinical data management.

Aptose Biosciences Inc. today announced that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global, clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it successfully completed its first-in-human Phase 1 study of CBP-174 designed to evaluate safety, tolerability, and pharmacokinetics (PK) in healthy adults.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant’s senior management will participate in the following September investor conferences.

Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.